Vnitr Lek 2026, 72(3):158-164 | DOI: 10.36290/vnl.2026.034

Secondary antibody deficiency - novel diagnostic and therapeutic approaches

Tomáš Milota
Ústav imunologie, 2. lékařská fakulta Univerzity Karlovy, Fakultní nemocnice Motol a Homolka, Praha

Secondary antibody immunodeficiencies (SAD) are a heterogeneous group of diseases of acquired immune disorders that arise under broad spectrum of internal and external factors. Unlike primary antibody immunodeficiencies, they are often accompanied by multiple components of the immune system being affected, either within the disease itself or as a result of its treatment. The picture is often accompanied by neutropenia, lymphopenia, hypocomplementemia, etc. According to etiology, SAD can be divided into loss hypogammaglobulinemia and SAD associated with impaired antibody production. We assess the total levels of immunoglobulins and specific antibodies in laboratory diagnostics, including diagnostic vaccination. The severity of immunodeficiency, along with the frequency of infections, is also determined by their etiology and severity. The basic therapeutic approach is to reduce the risk of infections. To reach it, we usually use three basic treatment pillars - antibiotic prophylaxis, vaccination, and immunoglobulin replacement therapy.

Keywords: secondary antibody deficiency, antibiotic prophalyxis, immunoglobulin replacement therapy.

Accepted: April 23, 2026; Published: May 18, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Milota T. Secondary antibody deficiency - novel diagnostic and therapeutic approaches. Vnitr Lek. 2026;72(3):158-164. doi: 10.36290/vnl.2026.034.
Download citation

References

  1. Kindle G, Alligon M, Albert MH, et al. Inborn errors of immunity: Manifestation, treatment, and outcome-an ESID registry 1994-2024 report on 30,628 patients. Journal of Human Immunity. 2025;1(3). Go to original source... Go to PubMed...
  2. Chovancova Z, Hlavackova E, Hakl R et al. First report from the Czech national registry of inborn errors of immunity (2012-2025). Front Immunol. 2025;16. Go to original source... Go to PubMed...
  3. Yazdani R, Azizi G, Abolhassani H, et al. Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management. Vol. 85, Scandinavian Journal of Immunology. 2017. Go to original source... Go to PubMed...
  4. Weifenbach N, Schneckenburger AAC, Lötters S. Global Distribution of Common Variable Immunodeficiency (CVID) in the Light of the UNDP Human Development Index (HDI): A Preliminary Perspective of a Rare Disease. J Immunol Res. 2020. Go to original source... Go to PubMed...
  5. Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. Frontiers in Immunology. 2019. Go to original source...
  6. Griggio V, Perutelli F, Salvetti C, et al. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Vol. 11, Frontiers in Immunology. 2020. Go to original source...
  7. Russell BM, Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int J Hematol. 2023;117(5). Go to original source... Go to PubMed...
  8. Wadhwa PD, Morrison VA. Infectious Complications of Chronic Lymphocytic Leukemia. Semin Oncol. 2006;33(2). Go to original source...
  9. Guarana M, Nucci M. Infections in patients with chronic lymphocytic leukemia. Hematol Transfus Cell Ther. 2023;45(3):387-93. Go to original source... Go to PubMed...
  10. Habibi MA, Alesaeidi S, Zahedi M, et al. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Vol. 11, Biology. 2022. Go to original source...
  11. Oksbjerg NR, Nielsen SD, Blinkenberg M, et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52. Go to original source... Go to PubMed...
  12. Opdam MAA, De Leijer JH, Den Broeder N, et al. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. Rheumatology (United Kingdom). 2023;62(1). Go to original source... Go to PubMed...
  13. Eldeniz FC, Gul Y, Yorulmaz A, et al. Evaluation of the 10 Warning Signs in Primary and Secondary Immunodeficient Patients. Front Immunol. 2022;13. Go to original source...
  14. Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology. 2022;149(5). Go to original source... Go to PubMed...
  15. Regina J, Doms J, Kampouri E, Gerber C, et al. Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management. Clinical Reviews in Allergy and Immunology. 2025;68. Go to original source... Go to PubMed...
  16. Bonilla FA. Update: Vaccines in primary immunodeficiency. Journal of Allergy and Clinical Immunology. 2018;141(2). Go to original source... Go to PubMed...
  17. Milota T, Smetanova J, Zelena H, et al. Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy. Int Immunopharmacol. 2023;125:111159. Go to original source... Go to PubMed...
  18. McQuilten ZK, Weinkove R, Thao LTP, et al. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. Blood Adv. 2024;8(7). Go to original source... Go to PubMed...
  19. de Albornoz SC, Higgins AM, Petrie D, et al. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. Blood Adv. 2024;8(9). Go to original source... Go to PubMed...
  20. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Vol. 50, European Respiratory Journal. 2017. Go to original source... Go to PubMed...
  21. Janssens Y, Joye J, Waerlop G, et al. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation. Vol. 13, Frontiers in Immunology. 2022. Go to original source...
  22. Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Defending against SARS-CoV-2: The T cell perspective. Vol. 14, Frontiers in Immunology. 2023. Go to original source...
  23. Sánchez-Menéndez C, Zurdo A, Corona M, et al. Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis. Front Immunol. 2025;16. Go to original source... Go to PubMed...
  24. Jolles S, Michallet M, Agostini C, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Vol. 106, European Journal of Haematology. 2021. Go to original source... Go to PubMed...
  25. Patel V, Cowan J. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Review of Clinical Immunology. 2020. doi: 10.1080/1744666X.2020.1788939. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.